These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21517778)

  • 1. Medicinal chemistry of sirtuin inhibitors.
    Chen L
    Curr Med Chem; 2011; 18(13):1936-46. PubMed ID: 21517778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of NAD+ dependent histone deacetylases (sirtuins).
    Neugebauer RC; Sippl W; Jung M
    Curr Pharm Des; 2008; 14(6):562-73. PubMed ID: 18336301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors to understand molecular mechanisms of NAD(+)-dependent deacetylases (sirtuins).
    Lawson M; Uciechowska U; Schemies J; Rumpf T; Jung M; Sippl W
    Biochim Biophys Acta; 2010; 1799(10-12):726-39. PubMed ID: 20601279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition.
    Trapp J; Jochum A; Meier R; Saunders L; Marshall B; Kunick C; Verdin E; Goekjian P; Sippl W; Jung M
    J Med Chem; 2006 Dec; 49(25):7307-16. PubMed ID: 17149860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Current State of NAD
    Schiedel M; Robaa D; Rumpf T; Sippl W; Jung M
    Med Res Rev; 2018 Jan; 38(1):147-200. PubMed ID: 28094444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel 3-arylideneindolin-2-ones as inhibitors of NAD+ -dependent histone deacetylases (sirtuins).
    Huber K; Schemies J; Uciechowska U; Wagner JM; Rumpf T; Lewrick F; Süss R; Sippl W; Jung M; Bracher F
    J Med Chem; 2010 Feb; 53(3):1383-6. PubMed ID: 20030343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Sirtuins: Substrate Specificity and Inhibitor Design.
    Rajabi N; Galleano I; Madsen AS; Olsen CA
    Prog Mol Biol Transl Sci; 2018; 154():25-69. PubMed ID: 29413177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Second Generation Activity-Based Chemical Probes for Sirtuins.
    Curry AM; Barton E; Kang W; Mongeluzi DV; Cen Y
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33375102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer agents targeted to sirtuins.
    Kozako T; Suzuki T; Yoshimitsu M; Arima N; Honda S; Soeda S
    Molecules; 2014 Dec; 19(12):20295-313. PubMed ID: 25486244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAD(+) -dependent histone deacetylases (sirtuins) as novel therapeutic targets.
    Schemies J; Uciechowska U; Sippl W; Jung M
    Med Res Rev; 2010 Nov; 30(6):861-89. PubMed ID: 19824050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How much successful are the medicinal chemists in modulation of SIRT1: A critical review.
    Kumar A; Chauhan S
    Eur J Med Chem; 2016 Aug; 119():45-69. PubMed ID: 27153347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biology, Chemistry, and Pharmacology of Sirtuins.
    Bedalov A; Chowdhury S; Simon JA
    Methods Enzymol; 2016; 574():183-211. PubMed ID: 27423863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in inhibitors of sirtuin1/2: an update and perspective.
    Zhou Z; Ma T; Zhu Q; Xu Y; Zha X
    Future Med Chem; 2018 Apr; 10(8):907-934. PubMed ID: 29642711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of NAD+ dependent histone deacetylases (sirtuins) in ageing.
    Trapp J; Jung M
    Curr Drug Targets; 2006 Nov; 7(11):1553-60. PubMed ID: 17100594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Basis of Sirtuin 6 Inhibition by the Hydroxamate Trichostatin A: Implications for Protein Deacylase Drug Development.
    You W; Steegborn C
    J Med Chem; 2018 Dec; 61(23):10922-10928. PubMed ID: 30395713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism-Based Inhibitors of the Human Sirtuin 5 Deacylase: Structure-Activity Relationship, Biostructural, and Kinetic Insight.
    Rajabi N; Auth M; Troelsen KR; Pannek M; Bhatt DP; Fontenas M; Hirschey MD; Steegborn C; Madsen AS; Olsen CA
    Angew Chem Int Ed Engl; 2017 Nov; 56(47):14836-14841. PubMed ID: 29044784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological characterisation of sirtuin inhibitors based on the tenovins.
    McCarthy AR; Pirrie L; Hollick JJ; Ronseaux S; Campbell J; Higgins M; Staples OD; Tran F; Slawin AM; Lain S; Westwood NJ
    Bioorg Med Chem; 2012 Mar; 20(5):1779-93. PubMed ID: 22304848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus.
    Dewanjee S; Vallamkondu J; Kalra RS; Chakraborty P; Gangopadhyay M; Sahu R; Medala V; John A; Reddy PH; De Feo V; Kandimalla R
    Cells; 2021 May; 10(6):. PubMed ID: 34071497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative modeling and benchmarking data sets for human histone deacetylases and sirtuin families.
    Xia J; Tilahun EL; Kebede EH; Reid TE; Zhang L; Wang XS
    J Chem Inf Model; 2015 Feb; 55(2):374-88. PubMed ID: 25633490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on lysine deacylases targeting the expanding "acylome".
    Olsen CA
    ChemMedChem; 2014 Mar; 9(3):434-7. PubMed ID: 24375937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.